Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aloin is a naturally occurring anthrone C-glucoside and a hydroxyanthracene derivative found in the exudate of at least 68 Aloe species. It exists as a diastereoisomeric mixture of aloin A (barbaloin) and aloin B (isobarbaloin), both yellow-brown bitter compounds. Aloin acts primarily as a stimulant-laxative by inducing bowel movements through increased secretion of water and electrolytes in the intestine. It also exhibits anti-inflammatory, antioxidant, antimicrobial, anti-tumor (antiproliferative), and wound-healing properties. Mechanistically, it inhibits tyrosinase activity and has been shown to suppress inflammatory pathways such as NF-κB signaling and JAK1-STAT1/3 activation. Aloin may also inhibit proteasome activity in vitro[1][2][5][7]. Historically used for constipation relief and skin conditions (acne, burns), its use in over-the-counter laxatives was banned by the FDA due to concerns about carcinogenicity[1][4]. It remains present in some dietary supplements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aloin.